How Was Ozempic Approved by the FDA?
Ozempic (semaglutide), developed by Novo Nordisk, received approval from the U.S. Food and Drug Administration following a multi-year regulatory review process.
- December 5, 2016: Novo Nordisk submitted a New Drug Application (NDA 209637) seeking approval for a once-weekly injectable semaglutide (0.5 mg and 1 mg) to improve glycemic control in adults with type 2 diabetes.
- December 5, 2017: The FDA approved Ozempic for use alongside diet and exercise in adults with type 2 diabetes.
- March 20, 2019: Novo Nordisk submitted a supplemental application to expand Ozempic’s indication to include reduction of major cardiovascular events.
- January 16, 2020: The FDA approved Ozempic for reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
- May 28, 2021: Novo Nordisk sought approval for a higher 2 mg dose.
- March 28, 2022: The FDA approved the increased dosage, expanding prescribing flexibility.
- December 23, 2025: The FDA has approved a new oral form of semaglutide- the “Wegovy pill” (oral glucagon-like peptide-1 (GLP-1) receptor agonist) for long in duration weight loss for patients 18+who are obese or overweight. The new oral pill can reduce the chance of major adverse cardiovascular (CV) events in patients 18+ with a CV disease diagnosis who are obese or overweight.
This approval history reflects both the drug’s initial therapeutic purpose and subsequent efforts to broaden its clinical use.
Ozempic Warning Label Changes (2017–2025)
Since its approval, Ozempic’s safety label has undergone numerous updates, many based on post-marketing adverse event reports and emerging clinical data.
Initial FDA Warnings (2017)
At the time of approval, Ozempic carried a boxed warning—the FDA’s most serious safety warning—regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).
The original label also warned of:
- Pancreatitis
- Diabetic retinopathy complications
- Hypoglycemia (especially when used with insulin)
- Acute kidney injury (often linked to dehydration)
- Gastrointestinal effects such as nausea, vomiting, and constipation
2020: Cardiovascular Benefit Language Added
Following supplemental approval, the label was updated to state that Ozempic may:
Reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.
2021: Hypoglycemia and Hypersensitivity Updates
The FDA strengthened warnings related to:
- Increased risk of severe hypoglycemia when used with insulin or sulfonylureas
- Serious allergic reactions, including anaphylaxis and angioedema
Patients were specifically advised to monitor for symptoms and adjust accompanying medications where appropriate.
2022: Gallbladder Disease and Expanded Safety Risks
The Ozempic label was updated to include acute gallbladder disease, such as:
- Cholelithiasis (gallstones)
- Cholecystitis (inflammation of the gallbladder)
Additional warnings instructed patients to seek medical attention for symptoms like abdominal pain, fever, or jaundice.
Later in 2022, the label was further updated to address pregnancy-related risks, including background rates of birth defects and complications associated with poorly controlled diabetes.
2023: Ileus (Intestinal Blockage) Warning Added
In September 2023, the FDA required the addition of ileus, a serious intestinal blockage, to the post-marketing adverse reactions section.
This update reflected increasing reports of severe gastrointestinal complications, including delayed gastric emptying and bowel obstruction.
2024: Pulmonary Aspiration Risk
In November 2024, the label was updated to warn of pulmonary aspiration during procedures involving general anesthesia or deep sedation.
Patients are now advised to inform healthcare providers they are taking Ozempic prior to surgery due to the risk of stomach contents entering the lungs.
2025: Severe Gastrointestinal and Organ-Related Risks
In 2025, the FDA made several significant updates:
- Ozempic was labeled as not recommended in patients with severe gastroparesis
- Expanded warnings regarding:
- Acute pancreatitis (including fatal cases)
- Acute kidney injury due to dehydration
- Severe gastrointestinal adverse reactions
Additional adverse events added to the label included:
- Ileus and intestinal obstruction
- Severe constipation and fecal impaction
- Gallbladder-related conditions
- Neurological symptoms (e.g., dysesthesia)
- Hair loss (alopecia)
By October 2025, the FDA further emphasized the frequency and severity of gastrointestinal complications observed in both clinical trials and post-marketing data.
Boxed Warning: Thyroid C-Cell Tumors
Ozempic continues to carry a boxed warning for the risk of thyroid C-cell tumors.
The FDA warns that:
- Semaglutide caused thyroid tumors in animal studies
- It is unknown whether this risk applies to humans
- The drug is contraindicated in patients with:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Boxed warnings are the most serious safety alerts issued by the FDA and are reserved for risks that may result in severe injury or death.
Legal Implications
The evolving nature of Ozempic’s warning label is highly relevant in pharmaceutical litigation. Each label update may raise questions regarding:
- Whether risks were adequately disclosed to patients and physicians
- The timing of safety warnings relative to reported adverse events
- The manufacturer’s compliance with federal reporting requirements
As additional safety data emerges, Ozempic-related claims continue to develop, particularly in cases involving severe gastrointestinal injuries, pancreatitis, or other complications.
Ozempic’s regulatory history demonstrates a pattern seen with many widely used medications: initial approval followed by ongoing safety refinements. While the drug remains FDA-approved for type 2 diabetes and cardiovascular risk reduction, its label has expanded significantly to reflect a growing body of risk data.
Individuals who have experienced serious side effects should stay informed of these developments and may wish to seek legal guidance regarding their rights.